Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Cell Death Dis. 2020 Oct 3;11(10):826. doi: 10.1038/s41419-020-03028-1.
Psoriasis is characterized by keratinocyte hyperproliferation. While significant progress has been made in understanding the molecular mechanism regulating the proliferation of keratinocytes, little is known about the epigenetic factors that control this process. EZH2 and EZH2 mediated trimethylation of histone H3 lysine 27 (H3K27me3) was previously shown ectopically expressed in carcinoma and mediated proliferation, thereby we sought to clarify the role of EZH2-H3K27me3 in the proliferation of psoriatic keratinocyte. Interestingly, we found that EZH2 and H3K27me3 were both overexpressed in the epidermis of psoriatic lesional skin compared to normal skin. In vitro, the expression of EZH2 and H3K27me3 was stimulated in human keratinocytes treated with mixture of psoriasis-related cytokines pool (TNF-α, IFN-γ, IL-17A, and IL-22). Knockdown of EZH2 significantly reduced keratinocyte proliferative activity. Results from mRNA microarray analysis suggested that Kallikrein-8 (KLK8) might be the target gene of EZH2 in psoriatic keratinocytes. Overexpression or knockdown KLK8 could partially reverse the abnormal proliferation of keratinocytes caused by knockdown or overexpression of EZH2. In vivo, the inhibitor of EZH2, GSK126 could ameliorate the imiquimod-induced psoriasiform lesion. These results suggest that EZH2 might be a therapeutic target for the treatment of psoriasis.
银屑病的特征是角质形成细胞过度增殖。虽然在理解调节角质形成细胞增殖的分子机制方面已经取得了重大进展,但对于控制这一过程的表观遗传因素知之甚少。先前已经表明,EZH2 和 EZH2 介导的组蛋白 H3 赖氨酸 27(H3K27me3)三甲基化在癌中异常表达,并介导增殖,因此我们试图阐明 EZH2-H3K27me3 在银屑病角质形成细胞增殖中的作用。有趣的是,我们发现与正常皮肤相比,银屑病皮损皮肤的表皮中 EZH2 和 H3K27me3 均过度表达。在体外,用银屑病相关细胞因子混合物(TNF-α、IFN-γ、IL-17A 和 IL-22)处理人角质形成细胞后,EZH2 和 H3K27me3 的表达受到刺激。EZH2 的敲低显著降低了角质形成细胞的增殖活性。mRNA 微阵列分析的结果表明,激肽释放酶 8(KLK8)可能是 EZH2 在银屑病角质形成细胞中的靶基因。KLK8 的过表达或敲低可以部分逆转 EZH2 敲低或过表达引起的角质形成细胞异常增殖。在体内,EZH2 的抑制剂 GSK126 可以改善咪喹莫特诱导的银屑病样病变。这些结果表明 EZH2 可能是治疗银屑病的一个治疗靶点。